Clinical Trial Update: ACE Inhibition and Novel Cardiovascular Risk Factors [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 trial evaluating ACE inhibition and novel cardiovascular risk factors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Heart Disease
• Hypertension

Drugs mentioned

• ACE inhibitors

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Cardiovascular Diseases, Heart Diseases | Phase 2 | Status: COMPLETED